Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Evolving Practice Standards for Cancer Programs from the Commission on Cancer
By
M. Asa Carter, CTR
Cancer Care
,
Personalized Medicine
May 2012, Vol 3, No 3
What is the most important challenge faced by a person who is diagnosed with cancer today? Opinions will differ, but most patients want to be assured that they will work with a group of multispecialty physicians who will provide recommendations for care that provide the best possible outcomes, that all options for effective treatment will be available to them, that care will be provided in a safe and comfortable hospital or other facility, and that the healthcare staff will care about their problems and concerns with managing treatment, professional issues, and family issues.
Read More
Can Whole-Genome Sequencing Predict Future Cancer?
AACR Annual Meeting
May 2012, Vol 3, No 3
Chicago, IL—For the individual at average risk for disease, whole-genome sequencing (WGS)—mapping the sequence of one’s full set of genetic material—is not a crystal ball to reliably predict future health, according to a study presented at the 2012 American Association for Cancer Research meeting.
Read More
Metformin Protects Against Several Cancers
By
Richard Hyer
AACR Annual Meeting
May 2012, Vol 3, No 3
Chicago, IL—Metformin cannot seem to stay out of the news. This antidiabetes drug that is derived from the French lilac is now also thought to possibly protect against liver cancer, lower the risk for oral cancer, improve prognosis of pancreatic cancer in diabetic patients, and increase response to melanoma tumors with BRAF mutations when used in combination with a common cancer drug, according to several studies presented at the 2012 American Association for Cancer Research meeting.
Read More
Advances in Personalized Medicine: Focus on Prostate and Brain Cancers
By
Richard Hyer
AACR Annual Meeting
May 2012, Vol 3, No 3
Chicago, IL—Targeting prostate cancer with extreme accuracy, using tissue oxygen content to predict its recurrence, and using breast cancer drugs on brain tumors were a few highlights of a news conference on advances in personalized medicine at the 2012 American Association for Cancer Research meeting.
Read More
Coping with Cancer Drug Shortages: Practical Tips
By
Neil Canavan
ACCC Annual Meeting
May 2012, Vol 3, No 3
Baltimore, MD—According to Ernest Anderson, Jr, MS, RPh, System Vice President of Pharmacy, Steward Health Care System, Boston, MA, “If you’re not familiar with the drug shortage issue, you must be living under a rock.”
Read More
Cost-Containment Efforts Top Trend in Community Cancer Centers
By
Neil Canavan
ACCC Annual Meeting
May 2012, Vol 3, No 3
Baltimore, MD—Results from the latest survey of the Association of Community Cancer Centers (ACCC) membership suggest that although cancer centers have stepped up their efforts to introduce cost-reduction and revenue-enhancing initiatives, the rising tide of underinsured or uninsured patients with cancer is straining even the most optimistic of business plans.
Read More
eviti: Decision Support at the Point of Care for Oncologists
By
Arlene A. Forastiere, MD
Oncology
May 2012, Vol 3, No 3
An independent health information technology company, eviti, Inc, provides a suite of web-based decision-support services that connects and delivers value to all parties in the care process—patients receive quality care, physicians are assured payment, insurers pay for quality care only, and pharmacy benefit managers (PBMs) or specialty pharmacy improve adherence.
Read More
Updated NCCN Practice Guidelines in Oncology Include 3 New Panels
By
Audrey Andrews
NCCN Conference
May 2012, Vol 3, No 3
The National Comprehensive Cancer Network (NCCN) introduced 3 new panels to its Clinical Practice Guidelines in Oncology™ at its 2012 annual conference.
Read More
Cancer Diagnosis Increases Suicide Risk or CV Death in the First Few Weeks
NCCN Conference
May 2012, Vol 3, No 3
Patients receiving a diagnosis of cancer are at increased risk for suicide and other adverse health effects that are triggered by the trauma associated with such a diagnosis, according to results of a recent study (Fang F, et al.
N Engl J Med
. 2012;366:1310-1318).
Read More
NCCN Clinical Practice Guidelines Update
By
Audrey Andrews
NCCN Conference
May 2012, Vol 3, No 3
The 2012 updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ have elevated several drugs to category 1 recommendation and have changed the algorithm for work-up in some tumors. A synopsis of the key updates presented at the 2012 annual conference is reported here.
Read More
Page 290 of 330
287
288
289
290
291
292
293
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma